DOCSLIB.ORG

Analysis of Metals in Surface Water Samples

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Analysis of Metals in Surface Water Samples ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Annex I Analysis of metals in surface water samples Environmental Institute, s.r.o., Okružná 784/42, 972 41 Koš, Slovakia October 2020 EUWI+, Investigative monitoring of the Dnieper River Basin, October 2020 ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Surface water samples Cd (ug/L) Pb (ug/L) Hg (ug/L) Ni (ug/L) As (ug/L) Cr (ug/L) Cu (ug/L) Zn (ug/L) Metals – limit values 0.15** 1.2** 0.07*** 4** 24* 9.0* 1.6* 9.6* Table 1: Results of analyses of Sampling point 1 filtered <LOQ <LOQ <LOQ <LOQ 3.38 <LOQ 1.15 4.0 metals in surface water samples. Sampling point 2 filtered 0.547 <LOQ <LOQ 1.845 <LOQ 0.666 1.94 26.5 The values represent dissolved Sampling point 3 filtered <LOQ <LOQ <LOQ <LOQ 1.99 <LOQ 0.89 4.1 concentrations (after filtration of Sampling point 4 filtered <LOQ <LOQ <LOQ 1.33 <LOQ <LOQ 4.21 9.2 the samples). Numbers Sampling point 5 filtered 2.66 <LOQ <LOQ <LOQ <LOQ 2.35 9.39 20.6 highlighted in orange colour Sampling point 6 filtered <LOQ <LOQ <LOQ <LOQ 2.62 <LOQ 4.95 6.9 indicate exceedance of the Sampling point 7 filtered 0.345 <LOQ <LOQ <LOQ <LOQ 0.777 6.06 38.4 toxicity threshold values. Sampling point 8 filtered <LOQ <LOQ <LOQ <LOQ 2.65 <LOQ 1.03 61.7 Sampling point 9 filtered 0.129 <LOQ <LOQ <LOQ 2.29 0.85 5.36 16.4 Sampling point 10 filtered <LOQ <LOQ <LOQ 1.772 <LOQ <LOQ <LOQ 7.9 Sampling point 11 filtered 0.292 <LOQ <LOQ <LOQ <LOQ 1.31 0.82 11.9 Sampling point 12 filtered 0.328 <LOQ <LOQ <LOQ <LOQ 3.89 1.34 2.6 Sampling point 13 filtered <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 0.81 10.0 Sampling point 14 filtered <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 1.25 <LOQ Sampling point 15 filtered <LOQ <LOQ <LOQ <LOQ 3.30 <LOQ 2.58 20.0 Sampling point 16 filtered 0.408 <LOQ 0.04 2.515 3.72 0.186 2.86 8.8 Sampling point 17 filtered 0.092 <LOQ <LOQ 1.066 <LOQ <LOQ 1.38 18.8 Sampling point 18 filtered 0.097 <LOQ <LOQ <LOQ <LOQ <LOQ 0.82 <LOQ Sampling point 19 filtered 0.106 <LOQ <LOQ 1.982 2.27 <LOQ 1.62 17.2 Sampling point 20 filtered 0.155 <LOQ <LOQ 1.378 <LOQ 0.472 1.00 0.7 Sampling point 21 filtered <LOQ <LOQ <LOQ 1.11 4.91 <LOQ 1.97 7.8 Sampling point 22 filtered <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 1.29 30.3 Sampling point 23 filtered <LOQ <LOQ <LOQ <LOQ 4.95 <LOQ <LOQ 17.1 Sampling point 24 filtered <LOQ <LOQ <LOQ 1.641 <LOQ <LOQ 1.52 23.5 Sampling point 25 filtered <LOQ <LOQ <LOQ 1.339 3.01 <LOQ 2.58 20.9 Sampling point 26 filtered <LOQ <LOQ <LOQ 6.142 <LOQ <LOQ 1.25 16.5 Sampling point 27 filtered 0.105 <LOQ <LOQ 2.784 10.6 <LOQ 0.90 35.9 LOQ (ug/L) 0.091 0.780 0.035 0.977 1.742 0.180 0.550 0.108 * - AA-EQS in the Slovak legislation 2013 ** - AA-EQS for inland surface waters in the Directive 2013/39/EU *** - MAC-EQS for inland surface waters in the Directive 2013/39/EU EUWI+, Investigative monitoring of the Dnieper River Basin, October 2020 ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Annex II List of compounds included in the wide-scope target screening Environmental Institute, s.r.o., Okružná 784/42, 972 41 Koš, Slovakia October 2020 EUWI+, Investigative monitoring of the Dnieper River Basin, October 2020 ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Summary table of 2252 target compounds analysed in surface water and biota samples within the wide-scope target screening LOD LOQ NORMAN ID Analyte (ng/L) (ng/L) NS00006968 Aceclidine 1.51 4.99 NS00000453 Acetamiprid 4.90 16.2 NS00009677 Albendazole sulfone 1.17 3.86 NS00007702 Amantadine 2.26 7.45 NS00010870 Aminobenzimidazole (2-) 4.46 14.7 NS00000633 Amisulpride-N-Oxide 2.33 7.68 NS00000412 Amphetamine-Methyl (methamphetamine) 24.6 81.2 NS00000226 Antipyrine- 4-Acetamido 1.74 5.76 NS00000329 Antipyrine- 4-Formylamino 1.03 3.39 NS00000470 Atazanavir 2.24 7.41 NS00010385 Atenolol 7.38 24.4 NS00000314 Atenolol acid (Metoprolol acid) 6.37 21.0 NS00000262 Atrazine 2.59 8.55 NS00000255 Atrazine-2-hydroxy 4.74 15.6 NS00000254 Atrazine-desethyl-2-hydroxy (=Prometon-Hydroxy-Desisopropyl) 8.49 28.0 NS00009778 Azoxystrobin 0.783 2.58 NS00000374 Azoxystrobin acid 6.99 23.1 NS00000060 Benzamidine 1.18 3.88 NS00010260 Benzothiazole- 2-Amino 2.96 9.78 NS00008199 Benzothiazole -2-OH 1.73 5.72 NS00010261 Benzotriazole (BTR) 2.74 9.03 NS00008943 Benzotriazole- 5-Me / Benzotriazole -4-Me 3.57 11.8 NS00009929 Bisoprolol 5.41 17.9 NS00000437 Boscalid 1.93 6.36 NS00000273 Caffeine 2.73 9.02 NS00009281 Candesartan 36.7 121 NS00000207 Carbamazepine 1.03 3.41 NS00010437 Carbamazepine -10-Hydroxy 1.03 3.41 NS00008351 Carbamazepine-10.11-dihydro-10.11 dihydroxy 13.1 43.3 NS00000327 Carbamazepine-10.11-epoxide 13.9 45.8 NS00010265 Carbendazim 3.46 11.4 NS00000627 Cetirizine-N-Oxide 38.7 128 NS00008150 Climbazole 0.593 1.96 NS00010041 Clomazone (Command) 1.06 3.49 NS00008954 Clopidogrel 7.01 23.1 NS00000417 Clopidogrel Carbon acid 6.18 20.4 NS00009180 Clothiandin 2.87 9.46 NS00010263 Cotinine 1.80 5.93 NS00010478 Cotinine-Hydroxy 3.66 12.1 NS00000339 Cyclophosphamide 2.23 7.35 NS00000117 Cyproconazole 5.96 19.7 NS00000118 Cyprodinil 0.278 0.918 EUWI+, Investigative monitoring of the Dnieper River Basin, October 2020 ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš NS00000221 DEET (Diethyltoluamide) 0.233 0.769 NS00000212 Diclofenac 2.07 6.82 NS00010630 Didecyldimethylammonium (DADMAC (C10:C10)) 0.283 0.935 NS00000433 Difenoconazole 3.72 12.3 NS00000126 Dimetridazole 5.88 19.4 NS00008293 Dimoxystrobin 1.47 4.86 NS00010439 Diphenhydramine 1.42 4.70 NS00000265 Diuron 0.974 3.22 NS00000408 EDDP 2.87 9.48 NS00000604 Efavirenz 12.2 40.3 NS00009136 Epoxiconazole 0.932 3.08 NS00010438 Ethofumesate 8.97 29.6 NS00000281 Fluconazole 11.5 38.0 NS00008659 Fluoxastrobin 0.387 1.28 NS00000704 Flutriafol 1.21 3.98 NS00000303 Galaxolidone 6.81 22.5 NS00002652 Gibberellic acid 2.11 6.95 NS00011725 Griseofulvin 0.264 0.871 NS00000361 Imidacloprid 0.709 2.34 NS00000387 Irbesartan 7.47 24.7 NS00000260 Isoproturon 8.85 29.2 NS00000671 Isoxaben 0.731 2.41 NS00000216 Ketoprofen 4.06 13.4 NS00000354 Lamotrigine 7.94 26.2 NS00000419 Levamisol 2.55 8.43 NS00000027 Lidocaine 26.2 86.4 NS00011458 Lidocaine-Nor 2.61 8.61 NS00000595 Lidocaine-N-oxide 3.60 11.9 NS00008464 Linezolid 12.9 42.6 NS00008581 Lopinavir 0.878 2.90 NS00002063 Loratadine 0.262 0.864 NS00008822 Losartan 5.04 16.6 NS00000218 Mefenamic acid 17.6 58.1 NS00000622 Memantine 1.28 4.22 NS00003738 Metalaxyl 0.769 2.54 NS00010410 Metamitron 1.82 5.99 NS00010520 Metamitron-desamino 0.912 3.01 NS00000249 Metazachlor 0.891 2.94 NS00000558 Metconazole 1.83 6.04 NS00000333 Metformin 1.34 4.41 NS00000411 Methadone 3.89 12.9 NS00010464 Metobromuron 1.11 3.65 NS00000248 Metolachlor 0.0613 0.202 NS00000295 Metolachlor-ESA 5.32 17.6 NS00000059 Metolachlor-morpholinon 2.16 7.14 NS00000197 Metoprolol 3.32 11.0 EUWI+, Investigative monitoring of the Dnieper River Basin, October 2020 ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš NS00000455 Metribuzin-Desamino (DA) 3.00 9.90 NS00000213 Naproxen 21.3 70.4 NS00008411 Nicosulfuron 1.20 3.97 NS00010308 Octocrylene 51.4 170 NS00010016 Oxcarbazepine 0.672 2.22 NS00000287 Phenazone 2.94 9.70 NS00000585 Pheniramine N-Oxide 4.23 13.9 NS00009400 Phosphate-triethyl 1.11 3.67 NS00010268 Phthalate-Dimethyl 4.68 15.4 NS00010095 Phthalate-Di-n-butyl 13.2 43.6 NS00010885 Prochloraz 1.81 5.98 NS00010269 Prometryn 0.328 1.08 NS00000456 Propazine-2-hydroxy (Prometon-Hydroxy) 6.22 20.5 NS00000220 Propiconazole 3.09 10.2 NS00010600 Propoxur 4.58 15.1 NS00010886 Prothioconazole-desethio 3.75 12.36 NS00000390 Pyraclostrobin 0.265 0.876 NS00000340 Ritonavir 16.2 53.6 NS00000195 Sotalol 3.22 10.6 NS00000199 Sulfadimidine (Sulfamethazine) 12.9 42.7 NS00000233 Sulfamethazine-N4-Acetyl 6.82 22.5 NS00000268 Sulfamethoxazole 9.82 32.4 NS00000269 Sulfamethoxazole-N4-Acetyl (Impurity A) 20.9 68.8 NS00000225 Sulfapyridine 6.83 22.6 NS00000201 Sulfathiazole 19.6 64.8 NS00000280 Tebuconazole 0.401 1.32 NS00000258 Terbuthylazine 8.31 27.4 NS00007860 Terbuthylazine-desethyl 21.5 71.0 NS00007958 Thiabendazole 1.00 3.31 NS00000448 Thiacloprid 1.25 4.11 NS00000449 Thiacloprid-amide 19.7 65.1 NS00010175 Thiamethoxam 1.84 6.09 NS00000551 Tributylamine 0.281 0.929 NS00000211 Trimethoprim 4.51 14.9 NS00000341 Valsartan 5.70 18.8 NS00000347 Venlafaxine-D L-N O-Didesmethyl 4.02 13.2 NS00000630 Venlafaxine-N-oxide 2.76 9.10 NS00010634 2-Benzothiazolesulfonic acid 87.6 289 NS00011447 3,3-pentamethylene-4-butyrolactam 1.02 3.35 NS00010632 Benzophenone-4 69.7 230 NS00010610 Bisphenol S 30.0 99.1 NS00010591 Lauryl diethanolamide 0.851 2.81 NS00007448 Metazachlor BH 479-11 1.37 4.52 NS00014432 N-Cyclohexyl-2-benzothiazol-amine 0.337 1.11 NS00010386 Phenylbenzimidazole sulfonic acid 45.2 149 NS00001149 Picoxystrobin 1.53 5.06 EUWI+, Investigative monitoring of the Dnieper River Basin, October 2020 ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš NS00008140 Triethylcitrate 1.88 6.19 NS00000310 Secbumeton 0.639 2.11 NS00000584 Guanylurea 70.7 233 NS00000247 2.4-D 30.6 101 NS00009697 5-Chlorobenzotriazole 0.927 3.06 NS00000236 Bentazone 1.15 3.78 NS00000500 Chloramphenicol 0.155 0.512 NS00010496 Dinitrophenol-2-4- (DNP) 0.0292 0.0965 NS00014401 Diphenylphosphate 9.87 32.6 NS00000349 Fipronil 0.816 2.69 NS00000351 Fipronil-sulfide 1.17 3.86 NS00011514 Fludioxonil 0.305 1.01 NS00008630 Furosemide 27.1 89.3 NS00000343 Hydrochlorothiazide 29.5 97.3 NS00000159 Isofenphos 5.29 17.5 NS00000243 MCPA 14.8 49.0 NS00000697 Meclofenamic Acid 7.77 25.6 NS00001849 Methylparaben 0.434 1.43 NS00010148 Metolachlor CGA 368208 6.67 22.0 NS00007746 N-Butylbenzenesulfonamide
Load more

Recommended publications
  • Réglementation De La Pharmacie
    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0063698 A1 Hartwig (43) Pub
    US 2008 OO63698A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0063698 A1 Hartwig (43) Pub. Date: Mar. 13, 2008 (54) CRYSTALLIZATION INHIBITION OF DRUGS now abandoned, which is a continuation of applica IN TRANSIDERMAL DRUG DELIVERY tion No. 10/010,342, filed on Dec. 5, 2001, now SYSTEMIS AND METHODS OF USE abandoned. (75) Inventor: Rod Lawson Hartwig, Plantation, FL (60) Provisional application No. 60/251.294, filed on Dec. (US) 5, 2000. Correspondence Address: Publication Classification Noven Pharmaceuticals, Inc. Jay G. Kolman, Esq. (51) Int. Cl. 11960 S.W. 144 Street A6II 3/56 (2006.01) A6F 3/00 (2006.01) Miami, FL 33186 (US) A6IP 43/00 (2006.01) (73) Assignee: NOVEN PHARMACEUTICALS, A6F 3/02 (2006.01) INC. (52) U.S. Cl. ........................... 424/448; 424/449; 514/170 (57) ABSTRACT Appl. No.: 11/897,189 (21) The invention relates to compositions and methods for (22) Filed: Aug. 29, 2007 making a transdermal drug delivery system capable of achieving substantially zero-order kinetics for delivery of Related U.S. Application Data the active agent over a period of time in excess of 24 hours and at least 72 hours, comprising a pharmaceutically accept (63) Continuation of application No. 10/751,152, filed on able active agent carrier and a rosin ester which provides a Jan. 2, 2004, now abandoned, which is a continuation crystal inhibiting and drug stabilizing effect on the active of application No. 10/353,624, filed on Jan. 29, 2003, agents incorporated therein. 13 2 2 Patent Application Publication Mar.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Overview of Planned Or Ongoing Studies of Drugs for the Treatment of COVID-19
    Version of 16.06.2020 Overview of planned or ongoing studies of drugs for the treatment of COVID-19 Table of contents Antiviral drugs ............................................................................................................................................................. 4 Remdesivir ......................................................................................................................................................... 4 Lopinavir + Ritonavir (Kaletra) ........................................................................................................................... 7 Favipiravir (Avigan) .......................................................................................................................................... 14 Darunavir + cobicistat or ritonavir ................................................................................................................... 18 Umifenovir (Arbidol) ........................................................................................................................................ 19 Other antiviral drugs ........................................................................................................................................ 20 Antineoplastic and immunomodulating agents ....................................................................................................... 24 Convalescent Plasma ...........................................................................................................................................
    [Show full text]
  • Nucleosides, Nucleotides, Heterocyclic Compounds, Pyridine 2013
    Nucleosides, Nucleotides, Heterocyclic Compounds, Pyridine, Pyrimidine, Azaindole, Quinoline, Thiazole, Isatin, Phenanthrene, Thiophene We declare that some of the listed products might be protected by valid patents. They are only for scientific research and development purpose. They are not offered for sales in countries where the sales of such products constitutes patents infringement. The liability for patents checking and patents infringement is exclusive at buyers risk! I2CNS LLC CANNOT BE HELD LIABLE FOR ANY VIOLATIONS OF PATENT RIGHTS CAUSED BY CUSTOMERS. CAS No. Product Name and Description 26988-72-7 1-METHYL-DL-TRYPTOPHAN 68886-07-7 2-Fluoro-4-hydroxyphenylaceticacid 72607-53-5 N-(3-AMINOPROPYL)METHACRYLAMIDE 171049-41-5 7-AMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLICACIDTERT- BUTYLESTER 885280-38-6 (3-OXO-CYCLOHEXYL)-CARBAMICACIDTERT-BUTYLESTER 186826-86-8 MOXIFLOXACIN HCL 102735-53-5 L-CYCLOPROPYLALANINE 145100-50-1 2-[N,N-BIS(TRIFLUOROMETHYLSULFONYL)AMINO]PYRIDINE 143491-57-0 Emtricitabine 39809-25-1 2-Amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3,9-dihydropurin-6-one 147127-20-6 Tenofovir 716-39-2 2,3-NAPHTHALENEDICARBOXYLICANHYDRIDE 4333-62-4 1,3-DIMETHYLIMIDAZOLIUMIODIDE 108-45-2 m-Phenylenediamine 1961-72-4 R-(3)-HYDROXYMYRISTICACID 131-48-6 N-Acetylneuraminicacid 88196-70-7 (R)-1-(3-Methoxyphenyl)ethylamine 680-31-9 Hexamethylphosphoramide 486-66-8 Daidzein 872-50-4 1-Methyl-2-pyrrolidinone 425378-68-3 2-FLUORO-5-NITROPHENYLBORONICACIDPINACOLESTER 115651-29-1 5-ACETYL-2-AMINO-4-HYDROXYBENZOICACID 115269-99-3 N,N-BIS-BOC-N-ALLYLAMINE
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • Respiratory Stimulant Drugs in the Post-Operative Setting
    Respiratory Physiology & Neurobiology 189 (2013) 395–402 View metadata, citation and similar papers at core.ac.uk brought to you by CORE Contents lists available at ScienceDirect provided by Elsevier - Publisher Connector Respiratory Physiology & Neurobiology j ournal homepage: www.elsevier.com/locate/resphysiol Review ଝଝ Respiratory stimulant drugs in the post-operative setting ∗ Francis J. Golder , Matthew M. Hewitt, James F. McLeod Galleon Pharmaceuticals, Inc., 213 Witmer Road, Horsham, PA 19044, USA a r t i c l e i n f o a b s t r a c t Article history: Drug-induced respiratory depression (DIRD) is a common problem encountered post-operatively and Accepted 11 June 2013 can persist for days after surgery. It is not always possible to predict the timing or severity of DIRD due to the number of contributing factors. A safe and effective respiratory stimulant could improve Keywords: patient care by avoiding the use of reversal agents (e.g., naloxone, which reverses analgesia as well as Surgery respiratory depression) thereby permitting better pain management by enabling the use of higher doses Ventilation of analgesics, facilitate weaning from prolonged ventilation, and ameliorate sleep-disordered breathing Anesthesia peri-operatively. The purpose of this review is to discuss the current pharmaceutical armamentarium Analeptic Opioid of drugs (doxapram and almitrine) that are licensed for use in humans as respiratory stimulants and Hypoxia that could be used to reverse drug-induced respiratory depression in the post-operative period. We also discuss new chemical entities (AMPAkines and GAL-021) that have been recently evaluated in Phase 1 clinical trials and where the initial regulatory registration would be as a respiratory stimulant.
    [Show full text]
  • US8074644.Pdf
    USOO8074644B2 (12) United States Patent (10) Patent No.: US 8,074,644 B2 Hale et al. (45) Date of Patent: *Dec. 13, 2011 (54) METHOD OF FORMING AN AEROSOL FOR (56) References Cited NHALATION DELVERY (75) Inventors: Ron L. Hale, Sandia Park, NM (US); U.S. PATENT DOCUMENTS Craig C. Hodges, Walnut Creek, CA 1,239,634 A 9, 1917 Stuart (US); Peter M. Lloyd, Walnut Creek, CA (US); Daniel Mufson, Napa, CA (Continued) (US); Daniel D. Rogers, Oakland, CA (US); Soonho Song, Hillsborough, CA FOREIGN PATENT DOCUMENTS (US); Martin J. Wensley, Los Gatos, CA 2152684 1, 1996 CA (US); Daniel J. Myers, Mountain (Continued) View, CA (US); Jeffrey A. McKinney, Lafayette, CA (US); Reynaldo J. OTHER PUBLICATIONS Quintana, Redwood City, CA (US); U.S. Appl. No. 1 1/687,466, filed Mar. 16, 2007, Zaffaroni et al. Joshua D. Rabinowitz, Princeton, NJ (US) (Continued) (73) Assignee: Alexza Pharmaceuticals, Inc., Primary Examiner — Steven Douglas Mountain View, CA (US) (74) Attorney, Agent, or Firm — Swanson & Bratschun, (*) Notice: Subject to any disclaimer, the term of this L.L.C. patent is extended or adjusted under 35 (57) ABSTRACT U.S.C. 154(b) by 272 days. The present invention relates to the inhalation delivery of This patent is Subject to a terminal dis aerosols containing Small particles. Specifically, it relates to a claimer. method of forming an aerosol for use in inhalation therapy. In (21) Appl. No.: 12/471,070 a method aspect of the present invention, a method of forming (22) Filed: May 22, 2009 an aerosol for use in inhalation therapy is provided.
    [Show full text]